Skip to content
OpenCapital
Get started

Amneal Pharmaceuticals, Inc. AMRX Tax And Other Distribution To Noncontrolling Interest Financing Activities

Other financials

Income statement

See full
Revenue$722.5M+3.9%
Gross profit$320.1M+25.1%
Operating income$141.8M+41.3%
Net income$62.3M+411%
EPS (diluted)$0.19+375%

Balance sheet

See full
Cash & equivalents$197.7M+234%
Total debt$2.6B+17.7%
Total equity-$45.4M+65.5%
Total assets$3.5B+5.2%

Cash flow

See full
Operating cash flow-$26.7M-461%
CapEx$8.2M-37.9%
Free cash flow-$34.9M-507%

Valuation

See full
Market cap$5.17B+51.0%
Enterprise value$7.55B+33.4%
P/E42.4×—
P/S1.7×+0.5×

Profitability

See full
Gross margin38.7%+2.0pp
Operating margin14.3%+1.6pp
Net margin4%+3.6pp
FCF margin7.9%-1.0pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity127.9×+119×
Current ratio2.5×+1.1×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept amrx:TaxAndOtherDistributionToNoncontrollingInterestFinancingActivities.

The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amneal Pharmaceuticals, Inc.'s tax and other distribution to noncontrolling interest financing activities.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s tax and other distribution to noncontrolling interest financing activities?
Amneal Pharmaceuticals, Inc. (AMRX) reported tax and other distribution to noncontrolling interest financing activities of $7.15M in Q1 2026.
How has Amneal Pharmaceuticals, Inc.'s tax and other distribution to noncontrolling interest financing activities changed year-over-year?
Amneal Pharmaceuticals, Inc.'s tax and other distribution to noncontrolling interest financing activities increased by 10410.3% year-over-year, from $68K to $7.15M.